Home

Pfizer (PFE)

26.28
+0.09 (0.34%)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world

Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close26.19
Open26.13
Bid26.15
Ask26.17
Day's Range26.01 - 26.52
52 Week Range24.48 - 31.54
Volume349,997,940
Market Cap147.34B
PE Ratio (TTM)18.64
EPS (TTM)1.4
Dividend & Yield1.680 (6.39%)
1 Month Average Volume55,029,677
Created with Highcharts 11.4.8ZoomView 1 month1mView 3 months3mView 6 months6mView year to dateYTDView 1 year1yView allAll1 Jan 199521 Mar 2025All ▾19961998200020022004200620082010201220142016201820202022202419951995200020002005200520102010201520152020202020252025025507508GHighcharts.com

News & Press Releases

Buying These Dirt-Cheap Stocks Could Be a Brilliant Movefool.com
Via The Motley Fool · March 22, 2025
Looking For Yields: Pfizer, Spire, And TriCo Bancshares Are Consistent Moneymakersbenzinga.com
Via Benzinga · March 21, 2025
Which Is The Healthiest Investment: Merck Or Pfizertalkmarkets.com
Adeep dive into Merck and Pfizer, two of the biggest pharmaceutical companies out there.
Via Talk Markets · March 21, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · March 21, 2025
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressedbenzinga.com
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Via Benzinga · March 21, 2025
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBioinvestors.com
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio.
Via Investor's Business Daily · March 21, 2025
32-Year-Old Investor With Massive NVDA Gains And $350K Cash Asks Reddit: 'What's Stopping Me From Putting It All In SCHD?'benzinga.com
Investors are often driven by the pursuit of massive gains and few assets capture this ambition better than individual stocks–like Nvidia Corporation (NASDAQ:
Via Benzinga · March 20, 2025
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025fool.com
Via The Motley Fool · March 20, 2025
2 High-Yield Dividend Stocks That Are Bargain Buys Right Nowfool.com
Via The Motley Fool · March 20, 2025
1 Reliable Dividend Stock You Can Buy Now and Hold at Least a Decadefool.com
Via The Motley Fool · March 20, 2025
Curious about the most active S&P500 stocks in today's session?chartmill.com
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · March 19, 2025
Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billionbenzinga.com
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%.
Via Benzinga · March 19, 2025
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slidesbenzinga.com
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the epidemic.
Via Benzinga · March 19, 2025
3 Dividend Stocks to Buy for Reliable Passive Incomefool.com
Via The Motley Fool · March 19, 2025
4 Analysts Assess Pfizer: What You Need To Knowbenzinga.com
Via Benzinga · March 18, 2025
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning.
By Pfizer Inc. · Via Business Wire · March 18, 2025
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyondbenzinga.com
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
Via Benzinga · March 17, 2025
3 Value Stocks in the Doghouse
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Via StockStory · March 17, 2025
The Smartest Dividend Stocks to Buy With $150 Right Nowfool.com
Via The Motley Fool · March 17, 2025
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).
Via StockStory · March 14, 2025
Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (UPDATED)benzinga.com
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased costs in federal health programs.
Via Benzinga · March 13, 2025
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Yearfool.com
Via The Motley Fool · March 13, 2025
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Studybenzinga.com
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.
Via Benzinga · March 12, 2025
10 Highest Yielding Blue Chip Stocks Nowtalkmarkets.com
Blue-chip stocks are established, financially strong, and consistently profitable publicly traded companies.
Via Talk Markets · March 12, 2025
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Druginvestors.com
The companies are looking to use protein degradation to take on some forms of breast cancer.
Via Investor's Business Daily · March 11, 2025